Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3690 Development of a novel NET-nutrition screening tool to identify patients requiring nutrition-related intervention and support

Introduction: Patients with neuroendocrine tumors (NET) are at risk of malnutrition, nutrient malabsorption and dietary change. Existing validated malnutrition risk screening tools are not designed to capture complex NET-related nutrition issues.

Conference:

Presenting Author: Laing E

Authors: Laing E, Kiss N, Loeliger J, Steer B, Michael M,

Keywords: neuroendocrine, nutrition, screening, diet,

#3515 PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy

Introduction: Long-acting (LA) SSA therapy is a common long-term treatment for NETs, but real-world data on patients’ injection experience using the latest LA SSA designs/formulations are limited.

Conference:

Presenting Author: O'Toole D

Authors: O'Toole D, Prebtani A, Webb S, Houchard A, Gueguen D,

Keywords: acromegaly, injection site pain, lanreotide autogel/depot, neuroendocrine tumor, octreotide long-acting release syringe, patient survey,

#3467 Correlation study between 68Ga-DOTATOC PET/CT metrics and 177Lu-DOTATATE dosimetry for non-pancreatic neuroendocrine tumors

Introduction: 177Lu-DOTATATE therapy is validated for the management of well-differentiated metastatic, somatostatin receptor expressing non-pancreatic neuroendocrine tumors (npNETs). The evaluation of the tissue absorbed dose (D) could allow to assess the risk-benefit ratio of PRRT. Unfortunately, due its complexity, dosimetry study is hardly performed in routine.

Conference:

Presenting Author:

Authors: Texier J, Jocmek M, Dierickx L, Vallot D, Brillouet S,

Keywords: 68Ga-DOTATOC PET/CT, non-pancreatic neuroendocrine tumor, 177Lu-DOTATATE, dosimetry,

#3270 Exploration of Ga-68 DOTA PET radiomics to predict the absorbed dose of Lu-177 DOTATATE® therapy of midgut neuroendocrine tumors

Introduction: Lu-177 DOTATATE® is a proficient systemic irradiation with heterogeneous individual consequences due to tumor burden, uptake and elimination. Current dosimetry protocols seem not accurate enough to predict efficacy or toxicity.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Courbon F

Authors: Brahmi S, Vallot D, Vija L, Dierickx L, Courbon F,

Keywords: midgut NET, Ga DOTA PET CT, LuPRRT, PET metrics, SUV, tumor absorbed dose,

#3182 Cost of carcinoid syndrome (CS) In France: Analysis of the national health insurance database

Introduction: CS develops in approximately 20% of patients with neuroendocrine tumors (NET). The cost of its management has never been studied in France.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Walter T

Authors: Perrier M, Mouawad C, Gueguen D, Bouille C, Laborey M,

Keywords: carcinoid syndrome, resources, healthcare expenditure,